KBY Biotech Indexv0.0.34
Search
← Pipeline|Talaglumide

Talaglumide

NDA/BLA
CCC-7372
By C4 Therapeutics
Source: Trial-derived·Trials: 2
Modality
Vaccine
MOA
KIF18Ai
Target
SGLT2
Pathway
Wnt
TTR AmyloidosisPBCAsthma
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
~Jan 2019
→ ~Apr 2020
NDA/BLA
Jul 2020
→ Jan 2028
NDA/BLACurrent
NCT03625547
2,096 pts·TTR Amyloidosis
2020-07→2028-01·Not yet recruiting
NCT05002672
2,441 pts·Asthma
2023-12→2026-12·Not yet recruiting
4,537 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-259mo awayPh3 Readout· Asthma
2028-01-071.8y awayPh3 Readout· TTR Amyloidosis
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
NDA/BLA
Not yet…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-12-25 · 9mo away
Asthma
Ph3 Readout
2028-01-07 · 1.8y away
TTR Amyloidosis
Not yet recruiting|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03625547NDA/BLATTR AmyloidosisNot yet recr...2096eGFR
NCT05002672NDA/BLAAsthmaNot yet recr...2441EASI-75
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-7550PfizerPhase 3AβKIF18Ai
RHH-7558RochePhase 1SGLT2Anti-Tau
TiramavacamtenRochePreclinicalSGLT2PI3Ki
RibosacituzumabRocheApprovedCl18.2KIF18Ai
RHH-8482RochePhase 1BTKKIF18Ai
PexatenlimabNovartisPhase 1/2GPRC5DKIF18Ai
RimatenlimabNovo NordiskPhase 2/3SGLT2PI3Ki
TAK-1836TakedaPreclinicalEGFRKIF18Ai
DSN-7360Daiichi SankyoApprovedSGLT2BiTE
FixaglumideGenmabPhase 2/3WEE1KIF18Ai